Probiotics in Mild Alzheimer's Disease

• Status: Recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective is to investigate whether administration of probiotics to patients with mild Alzheimer's Disease (AD) reduces neuroinflammation, improves cognitive function and modifies neurophysiological measures, compared to a patient group that receives placebo (no active probiotics).

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nicosia
• Collaborator: Cyprus Institute of Neurology and Genetics

Criteria

Inclusion Criteria:

• Adults ≥65 years, able to give consent

• Mini-Mental State Examination (MMSE) scores 19-23 (mild AD)

• approximately equal male:female ratio

Exclusion Criteria:

• Inability to give consent

• other neurological disease

• relevant psychiatric disorders (e.g. major depression)

• gastrointestinal/metabolic conditions

• history of alcohol/substance dependence

• use of systemic antibiotics in the previous 6 months

• corticosteroid use

• immune stimulating medications

• immunosuppressive agents

• probiotics consumption in the previous 6 months.

• immunosuppression

• structural heart disease

• neutropenia

• radiation

• active intestinal disease